Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

C4 Therapeutics (CCCC) Profit After Tax (2019 - 2025)

C4 Therapeutics' Profit After Tax history spans 7 years, with the latest figure at -$20.5 million for Q4 2025.

  • For Q4 2025, Profit After Tax rose 40.73% year-over-year to -$20.5 million; the TTM value through Dec 2025 reached -$105.0 million, changed 0.3%, while the annual FY2025 figure was -$105.0 million, 0.3% changed from the prior year.
  • Profit After Tax reached -$20.5 million in Q4 2025 per CCCC's latest filing, up from -$32.2 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$15.7 million in Q4 2021 to a low of -$37.2 million in Q4 2022.
  • Average Profit After Tax over 5 years is -$27.7 million, with a median of -$27.2 million recorded in 2022.
  • Peak YoY movement for Profit After Tax: plummeted 137.64% in 2022, then skyrocketed 50.68% in 2024.
  • A 5-year view of Profit After Tax shows it stood at -$15.7 million in 2021, then crashed by 137.64% to -$37.2 million in 2022, then grew by 6.58% to -$34.8 million in 2023, then grew by 0.54% to -$34.6 million in 2024, then skyrocketed by 40.73% to -$20.5 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Profit After Tax are -$20.5 million (Q4 2025), -$32.2 million (Q3 2025), and -$26.0 million (Q2 2025).